Optimizing Prolonged Treatment in Myeloma Using MRD Assessment (OPTIMUM)

Date Added
September 9th, 2021
PRO Number
Pro00114332
Researcher
Hamza Hashmi

List of Studies

Keywords
Cancer
Summary

This study is for patients that have been diagnosed with multiple myeloma. The study drugs are Ixazomib and lenalidomide. The purpose of this study is to compare using lenalidomide and ixazomib to using lenalidomide and placebo. Participants will be on this study until disease progression or unacceptable toxicity.

Institution
MUSC
Recruitment Contact
Barbara Roe
843-652-1607
broe@tidelandshealth.org



-- OR --